Phibro Animal Health Corporation delivered a strong second quarter, with net sales increasing by 21% to $373.9 million and net income surging by $24.3 million to $27.5 million. Adjusted EBITDA also saw a significant rise of 41% to $68.1 million, primarily driven by the faster-than-expected uptake of the newly integrated MFA portfolio and sustained growth in nutritional specialty and vaccine offerings.

Phibro Animal Health Corporation delivered an outstanding start to fiscal year 2026, with net sales surging 40% to $363.9 million and adjusted diluted EPS doubling to $0.73. The Animal Health segment was the primary growth engine, increasing 55% due to strong demand for MFAs, nutritional specialties, and vaccines. The company also raised its fiscal year 2026 Adjusted EBITDA guidance.

Driven by the successful integration of the Zoetis MFA portfolio and broad-based growth across Animal Health, Phibro reported a 39% increase in revenue and a substantial rise in profitability for Q4 2025.

Phibro Animal Health Corporation delivered strong financial results for the third quarter of fiscal year 2025, with net sales increasing by 32% and net income surging by 148% compared to the same period last year. The growth was primarily driven by the acquisition of Zoetis's medicated feed additive portfolio, which significantly boosted Animal Health segment revenues.

Phibro Animal Health Corporation experienced substantial growth in the three months ended December 31, 2024, with net sales increasing by 24% to $309.3 million and net income rising by 50% to $3.185 million. This growth was largely driven by the acquisition of Zoetis's medicated feed additive portfolio and increased demand across its Animal Health segment.

Phibro Animal Health Corporation reported a strong first quarter with net sales increasing by 13% to $260.4 million and net income of $7.0 million. Adjusted EBITDA increased by 64% to $30.7 million, driven by strong performance in the Vaccines business and recovery in Mineral Nutrition and Performance Products. The company updated its fiscal year 2025 guidance, projecting net sales of $1.05 billion to $1.10 billion and adjusted EBITDA of $124 million to $132 million.

Phibro Animal Health Corporation reported a 7% increase in net sales for the fourth quarter ended June 30, 2024, reaching $273.2 million. Net income decreased to $0.8 million, with diluted earnings per share at $0.02. Adjusted EBITDA increased by 3% to $33.4 million, and adjusted diluted EPS increased by 10% to $0.41. The company provided financial guidance for fiscal year 2025, projecting net sales between $1.040 billion and $1.090 billion and adjusted EBITDA between $118 million and $126 million.

Phibro Animal Health Corporation announced its third quarter results, showing a 7% increase in net sales to $263.2 million and a 9% increase in Adjusted EBITDA to $29.7 million. However, net income decreased by $1.6 million to $8.4 million, and diluted earnings per share decreased by $0.04 to $0.21. The company has updated its financial guidance for the year ending June 30, 2024, projecting net income between $7 million and $12 million, and diluted EPS between $0.17 and $0.30.

Phibro Animal Health Corporation reported second quarter results with a net sales increase of 2% to $249.9 million. However, net income decreased by 82% to $1.3 million, and diluted earnings per share decreased by $0.15 to $0.03.

Phibro Animal Health Corporation reported a decrease in net sales by 1% to $231.3 million and a net loss of $8.0 million for the first quarter ended September 30, 2023. The company's Animal Health segment saw a 4% increase in net sales, while Mineral Nutrition and Performance Products experienced declines. Updated financial guidance for fiscal year 2024 includes net sales of $980 million to $1.02 billion and adjusted EBITDA of $106 million to $112 million.

Phibro Animal Health Corporation reported Q4 2023 results with net sales of $255.0 million, a slight decrease of $0.2 million. However, net income increased by $4.0 million to $11.5 million, and diluted EPS also increased by $0.10 to $0.28. The company provided FY 2024 guidance, projecting net sales of $1.0 to $1.05 billion and adjusted EBITDA of $115 to $121 million.

Phibro Animal Health Corporation reported a 3% increase in net sales, reaching $245.7 million, but experienced a 43% decrease in net income, which fell to $10.0 million. Diluted EPS also decreased by 43% to $0.25.

Phibro Animal Health Corporation reported a 5% increase in net sales, reaching $244.6 million, but a 59% decrease in net income, which fell to $7.2 million. The company saw growth in its Animal Health and Performance Products segments, while Mineral Nutrition experienced a decline. Increased SG&A expenses, including environmental remediation costs, impacted profitability.

Phibro Animal Health Corporation reported an 8% increase in net sales, reaching $232.5 million for the first quarter ended September 30, 2022. However, net income decreased by 41% to $3.9 million, and adjusted EBITDA saw a slight decrease of 1% to $22.1 million. The company reiterated its full-year net sales guidance of $960 million to $1 billion and adjusted EBITDA guidance of $113 million to $118 million.